Join our Community
Support ToI and remove all ads
Learn more
×

Gilead Sciences Inc.

A bottle containing the drug Remdesivir is shown by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, October 15, 2020. (Zsolt Czegledi/MTI via AP)
November 20, 2020, 1:44 pm
WHO advises against using drug remdesivir for treating COVID patients
UN organization claims the medicine, which has received approval as a coronavirus treatment from several health agencies, has ‘no important effect’ on improving survival chances
By Patrick Galey
Rubber stoppers are placed onto filled vials of the drug remdesivir at a Gilead manufacturing site in the United States, March 2020. (Gilead Sciences via AP)
October 23, 2020, 6:46 am
FDA approves first COVID-19 drug: antiviral remdesivir
Medicine found to cut recovery time by five days on average, but no studies have shown it improves chances of surviving the coronavirus
By MARILYNN MARCHIONE
Rubber stoppers are placed onto filled vials of the remdesivir at a Gilead manufacturing site in the US, in March 2020. (Gilead Sciences via AP)
June 16, 2020, 8:05 pm
Israel to accept COVID-19 drug remdesivir from US company
Government backs Health Ministry in authorizing Gilead Sciences’ donation of medicine
By ToI Staff and Agencies
A vial of the drug remdesivir is viewed during a press conference about the start of a study with the drug in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, April 8, 2020, amidst the coronavirus pandemic. (Ulrich Perrey / POOL / AFP)
June 1, 2020, 8:24 pm
Gilead stock drops amid mixed results on drug remdesivir’s effects on virus
Company-led study finds those who who got medication for 5 days improved 65%, while there was no proven difference when getting it for 10 days; more details to be published
By AP and ToI Staff
In this on May 19, 2020 file photo, a chemist holds a pack of hydroxychloroquine tablets in Mumbai, India. (AP/Rafiq Maqbool)
May 23, 2020, 5:01 pm
Big study casts more doubt on malaria drugs pushed by Trump as virus treatment
Researchers estimate death rate slightly higher among those taking hydroxychloroquine; separate study on remdesivir suggests benefit in treating COVID-19
By AP and ToI Staff
Illustrative: A cybersecurity expert stands in front of a map of Iran as he speaks to journalists about the techniques of Iranian hacking, on September 20, 2017, in Dubai, United Arab Emirates. (AP/Kamran Jebreili)
May 9, 2020, 4:24 am
Israeli firm uncovers Iran-linked attempt to hack US virus drugmaker Gilead
Pharmaceutical company is pioneering treatment for coronavirus; ClearSky cybersecurity outfit says Iran-connected hackers are targeting COVID-19 researchers, including in Israel
By ToI Staff
A vial of the drug remdesivir is viewed during a press conference about the start of a study with the drug in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany, April 8, 2020, amidst the coronavirus pandemic. (Ulrich Perrey / POOL / AFP)
May 4, 2020, 1:31 pm
Remdesivir results for virus encouraging but too early to celebrate — local CEO
FDA last week gave emergency approval to medicine produced by Gilead Sciences; it is believed to shorten illness time in some, but effect on mortality rates still unclear
By ToI Staff and AP
Illustrative: Blood samples (AP Photo/Martin Mejia)
May 2, 2020, 4:47 pm
New US test could detect virus before patients become infectious
Defense Department working on new blood-based screening that identifies body’s immune response, may find illness 4 days earlier than current swab tests
By ToI Staff and AP
Rubber stoppers are placed onto filled vials of the remdesivir at a Gilead manufacturing site in the US, in March 2020. (Gilead Sciences via AP)
May 2, 2020, 12:58 am
Trump announces emergency approval for 1st drug shown to help virus recovery
In preliminary US trial, Gilead Science’s remdesivir shortens recovery time by 4 days; cleared for use for hospitalized patients with ‘severe disease’
By MATTHEW PERRONE and MARILYNN MARCHIONE
A vial of Gilead Sciences' remdesivir drug is seen during a press conference about the start of a study with drug in particularly ill coronavirus patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020. (Ulrich Perrey/Pool/AFP)
April 29, 2020, 7:35 pm
Experimental drug declared by US as first effective treatment against COVID-19
Dr. Anthony Fauci says trial on patients shows GIlead Sciences remdesivir ‘can block this virus,’ American government to work to boost availability of the antiviral medication
By Martin Crutsinger, MARILYNN MARCHIONE and Anne D'Innocenzio
Johnny, the bus driver from East Jerusalem who recovered from the coronavirus, is released from hospital, photo undated. (Maya Tzaben/Baruch Padeh Medical Center)
March 30, 2020, 8:37 pm
Bus driver who was Israel’s first serious virus patient makes full recovery
Johnny, from East Jerusalem, drove a group of Greek tourists later found to be carrying coronavirus; was treated with Remdesivir, which was originally developed for Ebola
By ToI Staff
Illustrative: Cancer cells. (Pixabay)
From the WebDecember 10, 2017, 2:07 pm
Gilead Sciences acquires CDL for $567m
Globes: Cell Design Labs (CDL) is developing cancer therapies based on CAR T, likely to be the next generation of medications
Kite Pharma develops cell therapies in which the patient's own immune cells fight cancer. (YouTube screenshot)
October 19, 2017, 3:49 pm
Israeli-founded Kite Pharma gets FDA nod for cancer therapy
Firm started by Israeli-US oncologist Arie Belldegrun was acquired by US firm Gilead Sciences for almost $12 billion in August
By Shoshanna Solomon
Weizmann Institute's Prof. Zelig Eshhar holds a board that illustrates how the cancer treatment works with mice, August 29, 2017. (Shoshanna Solomon/Times of Israel)
August 30, 2017, 4:20 pm
Breakthrough Israeli cancer professor on prowl to ease other ills
Weizmann Institute’s Zelig Eshhar’s genetically engineered T-cells are at the heart of Kite Pharma’s $12 billion acquisition
By Shoshanna Solomon
Israeli-American oncologist Arie Belldegrun, founder of Kite Pharma. (YouTube screenshot)
August 28, 2017, 6:55 pm
Gilead to buy Israeli-founded Kite Pharma for nearly $12 billion
The US firm, founded in 2009 by Israeli-US oncologist Arie Belldegrun, develops cell therapies for cancer treatments
By Shoshanna Solomon
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.